Sysmex launches first IVD JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms covered under health insurance in Japan: ipsogen JAK2 DX Reagent.https://www.sysmex.co.jp/en/news/2020/200106.html …
-
-
Important milestone for many patients to be tested for the JAK2 V617F mutation which presence is established as one of the major diagnostic criteria for MPN in the WHO 2016 guideline for the classification of myeloid neoplasms and acute leukemia: https://doi.org/10.1182/blood-2016-03-643544 …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.